Intraperitoneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers

Brian W. Loggie, J. M. Sterchi, A. T. Rogers, S. Lentz, H. Holmesle, D. Charles, D. Sundberg

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

A limited phase I pilot study of intraperitoneal hyperthermic chemotherapy (IPHC) in patients with carcinomatosis peritonei is reported. Seven adult patients with extensive carcinomatosis peritonei from gastrointestinal (n=6) or ovarian (n=1) primary cancer confined to the abdominopelvic cavity were treated. Bowel resection with anastomosis was done in 4 patients, and all had gross residual disease. The heated peritoneal perfusion with Mitomycin C (MMC), 30 mg, lasted 2-hours. No postoperative deaths, wound infections, subphrenic abscesses, or bowel leaks occurred. Two patients had self-limited serous wound leaks. Grade 3 neutropenia and grade 1 thrombocytopenia occurred; in one patient. Patients were discharged 9 to 23 days (median 11 days) postoperatively and median survival was 123 days (45 to 185). Malignant ascites present in 5 patients pre-IPHC was no longer present in 3 of those patients at discharge. Maximal mean MMC levels (μg/ml±SD; n=5) in perfusion fluid were 5.33±1.37, falling to 2.30±1.34 at 2 hours. Based on this limited trial, IPHC appears technically feasible, relatively safe, and warrants further clinical study in the treatment of disseminated intraperitoneal malignant disease.

Original languageEnglish
Pages (from-to)78-81
Number of pages4
JournalRegional Cancer Treatment
Volume7
Issue number2
StatePublished - 1995
Externally publishedYes

Fingerprint

Gastrointestinal Neoplasms
Ovarian Neoplasms
Drug Therapy
Mitomycin
Perfusion
Subphrenic Abscess
Carcinoma
Surgical Wound Infection
Patient Discharge
Neutropenia
Ascites
Survival
Wounds and Injuries

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology

Cite this

Loggie, B. W., Sterchi, J. M., Rogers, A. T., Lentz, S., Holmesle, H., Charles, D., & Sundberg, D. (1995). Intraperitoneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers. Regional Cancer Treatment, 7(2), 78-81.

Intraperitoneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers. / Loggie, Brian W.; Sterchi, J. M.; Rogers, A. T.; Lentz, S.; Holmesle, H.; Charles, D.; Sundberg, D.

In: Regional Cancer Treatment, Vol. 7, No. 2, 1995, p. 78-81.

Research output: Contribution to journalArticle

Loggie, BW, Sterchi, JM, Rogers, AT, Lentz, S, Holmesle, H, Charles, D & Sundberg, D 1995, 'Intraperitoneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers', Regional Cancer Treatment, vol. 7, no. 2, pp. 78-81.
Loggie, Brian W. ; Sterchi, J. M. ; Rogers, A. T. ; Lentz, S. ; Holmesle, H. ; Charles, D. ; Sundberg, D. / Intraperitoneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers. In: Regional Cancer Treatment. 1995 ; Vol. 7, No. 2. pp. 78-81.
@article{65d06e1097454dc59936514d6371e7a4,
title = "Intraperitoneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers",
abstract = "A limited phase I pilot study of intraperitoneal hyperthermic chemotherapy (IPHC) in patients with carcinomatosis peritonei is reported. Seven adult patients with extensive carcinomatosis peritonei from gastrointestinal (n=6) or ovarian (n=1) primary cancer confined to the abdominopelvic cavity were treated. Bowel resection with anastomosis was done in 4 patients, and all had gross residual disease. The heated peritoneal perfusion with Mitomycin C (MMC), 30 mg, lasted 2-hours. No postoperative deaths, wound infections, subphrenic abscesses, or bowel leaks occurred. Two patients had self-limited serous wound leaks. Grade 3 neutropenia and grade 1 thrombocytopenia occurred; in one patient. Patients were discharged 9 to 23 days (median 11 days) postoperatively and median survival was 123 days (45 to 185). Malignant ascites present in 5 patients pre-IPHC was no longer present in 3 of those patients at discharge. Maximal mean MMC levels (μg/ml±SD; n=5) in perfusion fluid were 5.33±1.37, falling to 2.30±1.34 at 2 hours. Based on this limited trial, IPHC appears technically feasible, relatively safe, and warrants further clinical study in the treatment of disseminated intraperitoneal malignant disease.",
author = "Loggie, {Brian W.} and Sterchi, {J. M.} and Rogers, {A. T.} and S. Lentz and H. Holmesle and D. Charles and D. Sundberg",
year = "1995",
language = "English",
volume = "7",
pages = "78--81",
journal = "Regional Cancer Treatment",
issn = "0935-0411",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Intraperitoneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers

AU - Loggie, Brian W.

AU - Sterchi, J. M.

AU - Rogers, A. T.

AU - Lentz, S.

AU - Holmesle, H.

AU - Charles, D.

AU - Sundberg, D.

PY - 1995

Y1 - 1995

N2 - A limited phase I pilot study of intraperitoneal hyperthermic chemotherapy (IPHC) in patients with carcinomatosis peritonei is reported. Seven adult patients with extensive carcinomatosis peritonei from gastrointestinal (n=6) or ovarian (n=1) primary cancer confined to the abdominopelvic cavity were treated. Bowel resection with anastomosis was done in 4 patients, and all had gross residual disease. The heated peritoneal perfusion with Mitomycin C (MMC), 30 mg, lasted 2-hours. No postoperative deaths, wound infections, subphrenic abscesses, or bowel leaks occurred. Two patients had self-limited serous wound leaks. Grade 3 neutropenia and grade 1 thrombocytopenia occurred; in one patient. Patients were discharged 9 to 23 days (median 11 days) postoperatively and median survival was 123 days (45 to 185). Malignant ascites present in 5 patients pre-IPHC was no longer present in 3 of those patients at discharge. Maximal mean MMC levels (μg/ml±SD; n=5) in perfusion fluid were 5.33±1.37, falling to 2.30±1.34 at 2 hours. Based on this limited trial, IPHC appears technically feasible, relatively safe, and warrants further clinical study in the treatment of disseminated intraperitoneal malignant disease.

AB - A limited phase I pilot study of intraperitoneal hyperthermic chemotherapy (IPHC) in patients with carcinomatosis peritonei is reported. Seven adult patients with extensive carcinomatosis peritonei from gastrointestinal (n=6) or ovarian (n=1) primary cancer confined to the abdominopelvic cavity were treated. Bowel resection with anastomosis was done in 4 patients, and all had gross residual disease. The heated peritoneal perfusion with Mitomycin C (MMC), 30 mg, lasted 2-hours. No postoperative deaths, wound infections, subphrenic abscesses, or bowel leaks occurred. Two patients had self-limited serous wound leaks. Grade 3 neutropenia and grade 1 thrombocytopenia occurred; in one patient. Patients were discharged 9 to 23 days (median 11 days) postoperatively and median survival was 123 days (45 to 185). Malignant ascites present in 5 patients pre-IPHC was no longer present in 3 of those patients at discharge. Maximal mean MMC levels (μg/ml±SD; n=5) in perfusion fluid were 5.33±1.37, falling to 2.30±1.34 at 2 hours. Based on this limited trial, IPHC appears technically feasible, relatively safe, and warrants further clinical study in the treatment of disseminated intraperitoneal malignant disease.

UR - http://www.scopus.com/inward/record.url?scp=0028837966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028837966&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028837966

VL - 7

SP - 78

EP - 81

JO - Regional Cancer Treatment

JF - Regional Cancer Treatment

SN - 0935-0411

IS - 2

ER -